Eli Lilly announces $6.5B manufacturing plant in Houston, boosting investment from initial proposal
The $6.5 billion Houston facility will create 615 permanent jobs and 4,000 construction jobs while producing orforglipron and other small molecule drugs to reduce foreign API dependence.
- Eli Lilly plans to build a new $6.5 billion manufacturing facility for small molecule drugs in Houston, Texas.
- The facility will focus on producing Eli Lilly's potential obesity and diabetes drug orforglipron and create 615 new jobs in the area.
- Construction on the 236-acre site is expected to begin this year and be completed within 5 years, generating around 4,000 construction jobs.
48 Articles
48 Articles
Eli Lilly announces second major investment in US manufacturing
The pharmaceutical company Eli Lilly announced on Tuesday that it will build a $6.5 billion facility in Texas, marking the company’s second multibillion-dollar U.S. investment this month. The Indiana-based company announced in February that it would be making four distinct manufacturing investments in 2025 across the United States, with the goal of bringing 13,000 domestic jobs to the American economy. Eli Lilly recently announced the first of t…
Eli Lilly to Construct $6.5 Billion Manufacturing Facility in Houston
Pharmaceutical giant Eli Lilly and Company has announced plans to build a $6.5 billion manufacturing facility in Houston and is expected to create more than 4,600 manufacturing and construction jobs. Construction at the city’s Generation Park is slated to begin in 2026 and become fully operational by 2031. In a Sept. 23 statement, Lilly revealed it will be manufacturing next-generation synthetic medicine active pharmaceutical products at the Hou…
Eli Lilly announces weight-loss drug to be manufactured at $6.5 billion site in Houston
The multibillion-dollar investment will result in more than 600 permanent jobs, according to the company. The manufacturing hub is slated to be built at Generation Park near Lake Houston and will produce a new weight-loss drug.
Coverage Details
Bias Distribution
- 88% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium